Transcatheter Mitral Valve Repair and Replacement Market provides an in-depth an

Posted by andrew on October 7th, 2019

This is a new technology, because many healthcare professionals and individuals do not know the benefits of surgery. The transcatheter mitral valve repair and replacement market has emerged as an effective treatment option for symptomatic severe mitral regurgitation (MR) in patients who are considered untreatable or at high surgical risk for mitral valve surgery.

Transcatheter Mitral Valve Repair and Replacement Market is expected to reach at ,878 million (both repair and replacement valves) by 2023, registering a CAGR of 30.0% from 2017 to 2023. The mechanical valves segment accounted for maximum share of the total market in 2016.

A mitral valve is a heart valve that allows blood to flow from the heart chamber to the left atrium and to another valve called the left ventricle. The mitral valve keeps blood flow in the proper direction and prevents blood from flowing back. Valve repair and replacement is performed when the left ventricle does not have enough blood, which can lead to bacterial endocarditis, congestive heart failure, and even sudden death.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/4512

The report provides a comprehensive analysis of the key players operating in the global transcatheter mitral valve repair & replacement market such as

• LivaNova Plc
• Abbott Laboratories
• Biotronik Pvt Ltd
• Edward Lifesciences
• Medtronic Plc
• Neovasc Inc.
• NeoChord
• St. Jude Medical
• Direct Flow Medical Inc.
• Colibri Heart Valve LLC.

The other players in the value chain of the global transcatheter mitral valve repair and replacement market include Venus Medtech, HLT Medical, Transcatheter Technologies GmbH, MValve Technologies, Coramaze Technologies GmbH, and Mardil Medical.

Increased elderly population and increased mitral valve disorders are driving market growth. In addition, innovation and introduction of new mitral valves are other factors that drive market growth. The main constraints observed in this market are strict regulatory controls and the high cost of mitral valve surgery and the high risks associated with these procedures. In addition, the rise in health care costs and the emergence of developing countries will provide opportunities for key market players.

The application of mitral stenosis is expected to maintain its predominance during the forecast period due to the high prevalence of mitral stenosis caused by rheumatic fever, an infectious heart disease. This has created significant demand for transcatheter mitral valve repair and replacement devices.